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AbstrAct
Introduction Patient-centred care is essential to 
the delivery of healthcare; however, this necessitates 
direct patient involvement in clinical decision-making 
and can be challenging for patients diagnosed with 
advanced non-small cell lung cancer where there may be 
misunderstanding of the extent of disease, prognosis and 
aims of treatment. In this context, decisions are complex 
and there is a need to balance the risks and benefits, 
including treatment with palliative intent. The aim of the 
PACT study is to identify the information and decision 
support needs of patients, leading to the development of 
an intervention to support patients with advanced lung 
cancer when considering treatment options.
Methods and analysis PACT is a five-stage, 
multimethod and multicentre study. Participants: Patients 
and health professionals will be recruited from three 
health boards. Methods: Non-participant observation of 
multidisciplinary team meetings (n=12) will be used to 
determine patients’ allocation to treatment pathways 
(stage I). Non-participant observation of patient–clinician 
consultations (n=20–30) will be used to explore 
communication of treatment options and decision-
making. Extent of participation in decision-making will 
be assessed using the Observing Patient Involvement in 
Shared Decision-Making tool. Interviews with patients 
(stage III) and their clinicians (stage IV) will explore 
the perception of treatment options and involvement 
in decision-making. Based on stages I–IV, an expert 
consensus meeting will finalise the content and format 
of the intervention. Cognitive interviews with patients will 
then determine the face validity of the intervention (stage 
V). Analysis: analysis will be according to data type and 
research question and will include mediated discourse 
analysis, thematic analysis, framework analysis and 
interpretative phenomenological analysis.
Ethics and dissemination Ethical approval has been 
granted. The study findings will contribute to and promote 
shared and informed decision-making in the best interest 
of patients and prudent healthcare. We therefore aim to 
disseminate results via relevant respiratory, oncology and 
palliative care journals and conferences.
IntroductIon
With an estimated 1.6 million of people dying 
every year, lung cancer remains a worldwide 
health problem1 and is the second most 
common cancer in the UK. In 2014, over 
40 000 new cases were diagnosed.2 Histolog-
ically, 80% of lung cancer relate to non-small 
cell type,2 which is incurable by cancer treat-
ments at later stages.
Unfortunately, lung cancer is often diag-
nosed when the cancer is in its advanced stage; 
in 2008, it was estimated that three-quarters 
of the newly diagnosed patients in England 
and Wales were diagnosed with a stage III or 
IV cancer.2 For non-small cell lung cancer 
(NSCLC), the 1-year and 10-year survival rates 
for stage III disease are 35% and 6%, respec-
tively, while for patients presenting with stage 
IV disease, the 1-year survival rate is 14%, with 
a median survival of 6–8 months.2
Although various targeted therapies have 
helped to increase survival rates for small 
subgroups of patients, combination chemo-
therapies remain the dominant approach 
towards treatment for NSCLC.3 4 For these 
Strengths and limitations of this study
 ► A multimethod qualitative approach, tailored to each 
phase, research question and data type, is used to 
inform the development of a complex intervention.
 ► The findings from this study will provide an in-depth 
analysis of key turning points influencing information 
sharing, communication and decision-making 
between patients and clinicians when considering 
treatment options following a diagnosis of advanced 
lung cancer over time.
 ► Multidisciplinary teams located in Wales are used 
and their meeting proceedings might not entirely 
represent the rest of the UK.
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Figure 1 The lung cancer patient pathway. MDT, 
multidisciplinary team; PET, positron emission tomography.
patients, who cannot be offered curative treatments, the 
National Institute for Health and Clinical Excellence5 
guidelines highlight the potential benefit of palliative 
care and recommend that patients who may benefit from 
palliative care services should be referred without delay.
Patient involvement in decision-making
From a societal perspective, lung cancer also raises issues 
of inequalities. Lung cancer is strongly associated with 
smoking, which, similarly to other poor health-related 
lifestyle behaviours, is linked to socioeconomic status.6 
In the UK, survival rates are poorer among patients 
from lower socioeconomic and minority ethnic groups 
and cancer severity at diagnosis increases with age.7 Age 
and socioeconomic status can in turn affect patients’ 
competency to actively engage in the consultation should 
they wish so. This means that any intervention aiming 
at improving patient participation in the consultations 
around treatment pathways will also lead to fairer access 
to healthcare.8
Shared decision-making (SDM) has been identified as 
the pinnacle of patient-centred care9 10 because it legit-
imises the patient’s right to make decisions about their 
care.11 Crucial to this process is a commitment from both 
parties to exchange information.12 13 Clinicians provide 
reliable evidence-based information on the likely bene-
fits and harms of interventions or actions, including any 
uncertainties and risks while patients convey information 
about the effect of the illness on their lives, their values 
and their preferences. Patient’s knowledge, preferences 
and priorities are taken into account alongside the clini-
cian’s expertise.
The UK Government aims to place patients’ needs, 
wishes and preferences at the heart of the clinical deci-
sion-making by making SDM the norm throughout the 
National Health Service (NHS).14 However, SDM is far 
from being routinely implemented alongside the patient 
clinical care pathway.11 Joseph-Williams and colleagues15 
reviewed patient-reported barriers and facilitators to SDM 
and identified two main themes: ‘how the healthcare 
system is organised’ (time, continuity of care, workflow 
and characteristics of the healthcare setting) and ‘what 
happens during the decision-making interaction’ (patient 
characteristics, power imbalance in the patient–clinician 
relationship, preparation for an SDM encounter and 
preparation for an SDM process). The authors conclude 
that patients need knowledge and feel empowered to 
participate in SDM and that any interventions aiming to 
improve SDM should take account of the relationships 
between these factors and focus on both sides.
Patients diagnosed with advanced NSCLC are having 
to live with a poor prognosis. Treatment decisions made 
within the context of end of life care are undoubtedly 
complex; however, it cannot be assumed that restricted 
options should be presented, and these patients are too 
sick to be involved in SDM. Belanger and colleagues 
concluded that although a substantial minority prefers 
passive roles, the majority of terminally ill patients want 
to participate in their treatment decisions.16 Unmet infor-
mation needs, unrealistic expectations, the way options 
are framed and delaying decisions constitute barriers to 
SDM. These factors echo and complement findings by 
Joseph-Williams and colleagues.15 Patients with advanced, 
life-limiting cancer express a desire for full information, 
with two-thirds of patients wanting to actively participate 
in decision-making.17
For patients with lung cancer, Lifford18 found that 
SDM was not routinely implemented, patients’ individual 
values were not elicited and treatment decisions were not 
deliberated together.18 Patients experience significant 
misunderstandings concerning the extent of disease, 
prognosis and the aims of treatment, and there is evidence 
of an ongoing process of collusion concerning ‘false opti-
mism’ communicated and shared by patients and their 
physicians.19 Given the prior mediation of treatment 
management within multidisciplinary team (MDT) meet-
ings, which take place after initial diagnosis (figure 1), it 
is possible that patients are further disenfranchised from 
the decision-making process during the patient–clinician 
consultation stage, as they may not receive full disclosure 
of all available treatment options, including associated 
benefits and burdens, to help aid and inform their deci-
sion-making.17 20 Even when physicians discuss options 
between different treatments, they find difficult to discuss 
the option of no ‘treatment’ despite the advance stages of 
cancer disease.21
The limitations of available treatments for lung cancer, 
balanced against the increasing and compelling evidence 
for a combined approach of oncology and palliative care, 
indicate the need to enable clinicians to introduce pallia-
tive care as an option at an early stage.5 22 However, timely 
referral to palliative care services might be complicated 
by patient’s poor understanding of palliative care services 
and intentions23 and clinicians’ concern about removing 
hope24 although evidence in fact suggests that the 
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Figure 2 PACT study design. MDT, multidisciplinary team.
opposite is the case, with patients feeling more involved 
in decision-making when given the opportunity to speak 
about palliative care.25 26
The ability to discuss palliative care while managing 
its associated connotations is challenging; however, early 
palliative interventions can lead to less aggressive treat-
ment, limit futile treatments and reduce symptom severity 
and problems associated with medical interactions while 
improving patients’ quality of life, overall mood and satis-
faction with care.27–29 In addition to this, there is now a 
growing body of evidence to suggest that systemic anti-
cancer therapy (SACT) for certain patients and cancer 
characteristics is likely to increase early treatment-related 
mortality.30–34 Four of these studies were UK based and 
one included 9634 patients diagnosed with NSCLC.34
Patients want more information than their clinicians 
perceive they do,35 and physicians poorly predict these 
preferences within the context of palliative care.35 36 For 
all the above reasons, a clear understanding of the balance 
of risk and benefits of SACT treatment and other options, 
such as palliative care, and of patients’ preferences are 
critical to promote shared and informed decision-making 
in the best interest of patients and prudent healthcare.37
Aims and objectives
The PACT study aims to identify the information and deci-
sion support needs of patients diagnosed with advanced 
NSCLC and aims to develop an intervention to support 
those patients and their clinicians when considering 
treatment options, including SACT and/or referral to, or 
integration with, palliative care. The objectives are to:
1. Study how treatment decisions are determined 
for patients with lung cancer and how patients 
are allocated to treatment pathways during MDT 
interactions.
2. Explore communication of treatment options and 
capture patients’ involvement in decision-making 
during doctor-patient consultations.
3. Explore patients’ and clinicians’ understanding and 
attitudes towards the delivery of treatment options for 
lung cancer and risk/benefits.
4. Capture patients’ and clinicians’ experiences of their 
consultation meetings and discussions in relation to 
perceptions of the available treatment options and of 
their involvement in decision-making.
5. Develop and face-test an intervention to support 
patients and clinicians when considering treatment 
options.
Methods
study design
PACT is a prospective, multimethod and multicentre 
study. The data collection process is sequential and has 
been designed to generate a rich understanding of the 
treatment decision-making process for NSCLC, starting 
from the beginning point of the MDT meeting and 
ending with the oncology appointment with the patient, 
following the patient pathway within the UK healthcare 
system (figure 1).
The methodology comprises five stages (figure 2).
Stage I is a discrete event and will not influence partic-
ipant selection in the later stages of the project. The data 
collected in stages 2–4 will be related to the same patient/
doctor dyad. If a companion is present, they will be also 
invited and recruited to the study.
recruitment and sampling
Recruitment and data collection will take place in 
three NHS respiratory oncology clinics, set within three 
different health boards in Wales (see online supplemen-
tary 1). Participants’ enrolment started in 2015 and is 
expected to end in 2017.
observation of lung Mdt meeting (stage I)
The aim is to study how treatment decisions are deter-
mined and how patients are allocated to treatment 
pathways. Four lung MDT meetings will be observed for 
each health board. Consent for data collection will be 
negotiated via nominated chairpersons of the meeting. 
Information sheets and consent forms signed by all 
contributing members are required for an MDT meeting 
to be considered for data collection.
Direct non-participant observation will be employed.38 
Non-participant observation enables the recording of 
non-verbal communication, interactional behaviours 
and proxemics.39 40 Audio recording will minimise bias, 
securing the actual verbatim of participants’ interac-
tions.38 41 One or more researchers will observe the MDT. 
Researchers will be selected for their methodological 
experience, academic background and familiarity with 
the clinical environment. They will be seated away from 
observed communications and will keep initial field notes 
and manage the digital recorder. Field notes will specify 
date, time, location and study site (see online supplemen-
tary 2). Observations regarding meeting membership, 
seating arrangements, equipment used and time keeping 
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Table 1 Participants’ inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Over the age of 18 years Recommendation by the 
MDT for radical treatment 
of underlying lung cancer 
or best supportive care 
without SACT
In receipt of an advanced NSCLC 
diagnosis
Any factor that prohibits 
communication or 
comprehension, 
including an inability to 
communicate in English
Be the subject of discussions 
at an MDT where a decision/
recommendation was made 
for SACT (including first-line or 
second-line chemotherapy)
Able and willing to give informed 
consent
Communicate sufficiently to 
partake in an interview
MDT, multidisciplinary team; NSCLC, non-small cell lung cancer; 
SACT, systemic anti-cancer therapy.
will be made. Patient-specific observations will also be 
made, focusing on the presentation of the patient, any 
information provided and considered, the key contribu-
tors to discussion, the process of decision-making and the 
nature of negotiation or how this is managed. In-depth, 
descriptive and reflective notes recording the research-
er’s observations will be completed as soon as possible 
after each observed consultation.41 42
Thematic analysis and mediated discourse analysis will 
be used to analyse the MDT data. Thematic analysis43 will 
identify the most appropriate segments of data for further 
exploration with mediated discourse analysis. Thematic 
analysis will follow Brawn and Clarke’s model and use 
five phases to establish meaningful patterns and issues of 
potential interest: (a) familiarisation with the data, (b) 
generating initial codes, (c) searching for themes among 
codes, (d) reviewing themes and (e) defining and naming 
themes.44
The MDT meetings are events with established 
memberships, customs and practices, which may differ 
across health boards. Mediated discourse analysis, a focus 
on discourse in action in communities of practice, will be 
used to explore the interactions and discussions between 
MDT attendees, examining how treatment decisions are 
determined, as well as the communication patterns and 
decision-making processes of the MDT members.45 The 
focus of mediated discourse analysis is the whole inter-
section of group social practices, team dynamics, spatial 
dynamics and the cultural traditions of the team, of which 
discourse is a part. Hence, attention will be paid to the 
power dynamics of the meeting with a deeper analysis 
of critical or key moments of interactions which involve 
decisions, use of questions that explore risks and benefits 
of alternative options by different members of the team, 
agreement and disagreement in diagnosis and treatment 
recommendations.
observation of patient–clinician consultation (stage II)
Stage II aims to explore the communication of treatment 
options and to capture patient’s involvement in deci-
sion-making. It also aims to understand their perceptions 
of the discussion around treatment options.
Clinicians who work with patients to discuss treatment 
options at each of the three sites are eligible to partici-
pate. The researcher will discuss the project with them 
and provide information sheets and consent forms. Clini-
cians who agree to participate will sign individual consent 
forms before approaching patients about PACT.
Patients and their companions (ie, persons accompa-
nying patients to consultation meetings) will be offered 
recruitment to the study in order that their communica-
tions may also be captured. Clinicians will identify eligible 
patients after their MDT allocation to oncology. Between 
7 and 10 participants (and their respective clinicians) 
will be recruited from each health boards. Inclusion and 
exclusion criteria are listed in table 1.
The clinical team at each site will identify and intro-
duce the study to eligible patients. These prospective 
participants will be given an information sheet and a 
letter with a reply slip. When the reply slip is returned, 
the researcher(s) will contact the participant to discuss 
the study and, if willing, to arrange to meet prior to their 
consultation. Consent will be taken by the observing 
researcher at their next clinic appointment. Where family 
members or companions are present, consent will be also 
sought. The contribution of family members/carers may 
represent a core component of the consultation and it is 
therefore important to capture. If the patient does not wish 
to take part, then the consultation will not be recorded 
and the patient/family will not be recruited to the study. 
If a companion does not consent to the study (in contrast 
to the patient wish), then their verbatim will be removed 
from the transcriptions and it will not be included in the 
analysis. In the case that more than one consultation is 
needed for a decision to be made, the researchers will 
follow the patient at their next appointment(s), and they 
will record the subsequent consultations.
Patient–clinician consultations will be audio-recorded 
on digital recorders. The researcher will manage the 
digital recorder and write field notes during the consul-
tation. Observations will focus on proxemics, non-verbal 
communication and interactional behaviours. If partic-
ipants do not wish to consent to the researcher being 
present, they will be given the option of our audio-re-
corded consultations.
Patient–clinician consultations will be measured using 
the Observing Patient Involvement in Shared Deci-
sion-Making (OPTION) instrument46 V.3. OPTION 
is a validated process outcome measure used to study 
the extent to which clinicians involve patient in deci-
sion-making within clinical consultations. The instrument 
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Table 2 OPTION tool items
1. The clinician draws attention to an 
identified problem as one that requires a 
decision-making process
Identifying the 
problem
2. The clinician states that there is more 
than one way to deal with the identified 
problem (‘equipoise’)
Explaining 
equipoise
3. The clinician assesses patient’s 
preferred approach to receiving 
information to assist decision-making 
(eg, discussion in consultations, read 
printed material, assess graphical data, 
use videotapes or other media)
Assessing 
preferred 
approach
4. The clinician lists ‘options’ which can 
include the choice of ‘no action’
Listing options
5. The clinician explains the pros and 
cons of options to the patient (taking ‘no 
action’ is an option)
Explaining pros 
and cons
6. The clinician explores the patient’s 
expectations (or ideas) about how the 
problem(s) are to be managed
Exploring 
expectations
7. The clinician explores the patient’s 
concerns (fears) about how the 
problem(s) are to be managed
Explaining 
concerns
8. The clinician checks the patient has 
understood the information
Checking 
understanding
9. The clinician offers the patient explicit 
opportunities to ask questions during the 
decision-making process
Offering 
opportunities for 
questions
10. The clinician elicits the patient’s 
preferred level of involvement in 
decision-making
Eliciting preferred 
involvement
11. The clinician indicates the need 
for a decision-making (or deferring) 
stage (how the decision is made is 
not evaluated (could be paternalistic). 
How the decision is made between 
participants and who takes ‘control’ is 
not evaluated)
Indicating need for 
decision
12. The clinician indicates the need to 
review the decision (or deferment)
Indicating need to 
review/defer
OPTION, Observing Patient Involvement in Shared Decision-
Making.
has been used with a range of consultations.47 From the 
transcripts, the researcher will rate the clinician’s level of 
expertise for 12 ‘patient-involving’ behaviours on Likert-
type scales ranging from 0 (no attempt to perform the 
behaviour) to 4 (the behaviour is performed to a high 
standard); the sum of these scores are standardised to 
provide a score of 0–100 to indicate the ‘overall level of 
patient-involving competencies’ of the clinician during 
the consultation. Individual item scores will also be used 
to identify areas where additional information and/or a 
different approach to the presentation of the information 
may be of benefit. To validate results, a second researcher 
will independently score the consultations.
Thematic analysis43 will be used to explore in greater 
detail how treatment management options are presented 
to patients and their involvement in decision-making 
during their consultation with clinicians. Clinical 
members of the research team will assess any clinically 
orientated topics collected under the OPTION headings.
semi-structured interviews with patients (stage III)
Stage III aims at capturing patients’ experiences of 
their consultation in relation to perceptions of the 
available treatment options and their involvement in 
decision-making.
Patients and their companions who participated in 
stage II will be invited to face-to-face interviews. Infor-
mation regarding interviews will be provided after 
observations. Signed consent from patients and compan-
ions (where present) will be taken by the researcher prior 
to the interview, subject to the participant having at least 
24 hours to review the information sheets. Participants 
will be telephoned by the researcher within a week after 
their consultation to arrange a convenient date and time 
for the interview. Interviews will take place within 2 weeks 
of the observed consultation wherever possible and no 
later than 4 weeks. We would like to keep flexibility with 
the timeframe of 2–4 weeks, as some patients might start 
chemotherapy immediately after their consultation and, 
therefore, might not feel well enough to be interviewed 
that proximately. Similarly, if patients become too ill to 
participate after consultation, they will be withdrawn 
from the next stage of the study.
Semi-structured interviewing will be the primary data 
collection method for this stage.48 This will provide space 
for patients to share and reflect on thoughts and feel-
ings regarding consultation experiences while allowing 
researchers to specifically explore questions regarding 
patients’ understanding of treatment options and their 
involvement in treatment decision-making (see online 
supplementary 3). Questions are designed to mirror 
the OPTION instrument (see table 2), which will subse-
quently be used to inform data analysis.
The interviews will be conducted at a place of conve-
nience for the patients (eg, their home, at the clinic). If 
a physical location proves inconvenient, interviews will be 
conducted by telephone, using call-recording equipment. 
Interviews are expected to be approximately 30–60 min 
in length, and these may be terminated at any point if a 
patient participant indicates they wish to stop, if they are 
clearly fatigued or if they become unwell.
Interviews will be recorded and transcribed verbatim. 
Field notes made with participant’s permission will 
record details of specific incidents occurring during 
the interview and any non-verbal communication. If 
any participants wish to be interviewed over the phone, 
attention to decreased engagement and verbal probing 
to check on participants’ fatigue will be initiated by the 
researcher, whereas non-verbal communication will be 
missed.
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The right of the participant to refuse to participate in 
the study without giving reasons will be respected. Simi-
larly, the participant will remain free to withdraw at any 
time from the study. All data will be withdrawn at request.
In the event of participant distress due to discussion 
of sensitive topics, or if a clinical or work-related issue 
emerges, the researchers, using their experience, will 
react at the time and will refer the issue to the partici-
pant’s clinical team, with their permission.
A framework analysis49 50 approach will be used to 
explore the pre-determined areas of interest informed 
by the OPTION instrument. Interpretative phenome-
nological analysis (IPA) will be also used to explore key 
emergent themes from the semi-structured interviews, 
focusing on how patients interpret their experience of 
the consultation process.51 IPA aims to understand the 
meaning that events or states have for participants based 
on their subjective accounts. The transcript of each 
interview will be analysed sequentially, following four 
stages: (a) preliminary reading, (b) initial comments are 
grouped into themes, (c) connections between themes 
is developed until an organised master list and thematic 
account of the case is achieved and (d) subsequent tran-
scripts: new themes will be tested against the previous 
cases as non-recurring themes are tested against following 
cases. Connections across cases will be noted to identify a 
set of super-ordinate themes for the group.51
semi-structured interviews with clinicians (stage IV)
Stage IV aims to explore clinicians’ views on treatment 
management options for patients with lung cancer, their 
experiences in presenting these options to patients (with 
a focus on risk/benefit) and their perceptions on how 
involved patients are in their treatment decisions. Simi-
larly to phase III, face-to-face semi-structured interviews 
will be used and questions will follow the OPTION instru-
ment domains.
Clinicians participating in the observations of patient–
clinician consultations will be interviewed across the three 
different health boards. Clinicians will be consented to 
the interview at the same time as they consent to the 
observation of their patient consultations. Signed consent 
from the clinicians will be taken by the researcher at the 
time of interview subject to the participant having at least 
24 hours to review the information sheets.
The right of the clinician to refuse to participate in the 
study without giving reasons will be respected. Similarly, 
the clinician will remain free to withdraw at any time from 
the study and all data will be withdrawn at request.
Interviews will take place as soon as possible following the 
observations of clinician’s respective consultations. Clini-
cians will be interviewed at the clinician’s clinic or office 
according to preference. If a face-to-face interview is not 
feasible, a telephone interview may be offered instead. 
Interviews will be approximately 30–60 min in length.
In the event of clinician distress due to discussion of 
sensitive topics, or if a clinical or work-related issue 
emerges, the researchers, using their experience, will 
react at the time and, if needed, they will advise clini-
cians to contact the BMA Counselling Service52 or they 
will refer the issue to the National Counselling Service for 
Sick Doctors, with the participants’ permission.53
The interviews will be carried out by an experienced 
researcher under the remote supervision of a member of 
the research team. The researcher will digitally record the 
interview but may also make field notes (with the partici-
pant’s permission) to record incidents occurring during 
the interview, non-verbal communication or reactions at 
the time of the interview.
As with the patient interviews, IPA will be used to 
explore how clinicians make sense of their situations in 
their personal context according to individual experi-
ence, values and training.51
Intervention development (stage V)
Phases I–IV will form an appropriate theoretical frame-
work to guide the design, development and subsequent 
evaluation of the intervention.54 Stage V aims to develop 
an intervention and face-test it for its usability with a 
representative patient group. An expert panel of stake-
holders will be convened and consulted to identify key 
components of the intervention and refine the design, 
development and content of the intervention in a 
consensus meeting. Methodologists with expertise in 
SDM and complex interventions, patients, carers, clini-
cians (lung cancer nurse specialists, oncologists, chest 
physicians and general practitioners) and lay represen-
tatives will be invited as stakeholders. Experts will be 
identified via a review of the most relevant literature 
in the field as well as clinical networks. Lay and profes-
sional stakeholders will be identified using patient and 
public involvement (PPI) networks. Information sheets 
and consent forms will be distributed via e-mail. Signed 
consent will be taken before the meeting.
The stakeholders meeting will follow the nominal group 
technique approach.55 This structured group discussion 
ensures contribution from each participant while mini-
mising researcher bias. The expert consultation will help 
ensure that the appropriate evidence base is incorporated 
into the design of the intervention.
Group discussions will be recorded and transcribed 
verbatim. Field notes made with participant’s permission 
will be made by the researcher(s). Thematic analysis43 
and ranking exercises will be used to summarise the data.
The consensus meeting will lead to a national Delphi 
survey of the same stakeholders to prioritise items in 
relation to outcome measure, format and content of the 
proposed intervention.
The proposed intervention will be then face-tested for 
usability with a convenience sample of patients (n=10–
15). Each participant will also be asked to take part in 
follow-up cognitive interviews.56 Potential participants 
will be recruited via participating MDTs and given infor-
mation about the study. The inclusion and exclusion 
criteria applied within stage II will apply. Participants will 
be telephoned by a researcher and a convenient time and 
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place for interview will be arranged. Signed consent from 
participants will be taken at the time of interview by the 
researcher, allowing at least 24 hours to review the infor-
mation sheets.
Cognitive interviews are conducted face to face. Partic-
ipants will be asked to answer questions outlined within 
the intervention tool, with the aim of collecting informa-
tion about the content, format and ease of understanding 
regarding the proposed intervention.57 Both ‘think 
aloud’ and ‘probe’ cognitive interviews techniques will be 
applied.56
Scripted and spontaneous probing will be used, 
following Willis’56 taxonomy of six categories: compre-
hension, paraphrasing, confidence judgement, recall, 
specific probes and general probes. The ‘scripted’ 
approach ensures that important aspects of the inter-
vention are addressed. Complementing this approach, 
‘spontaneous’ probing allows for an element of flexibility, 
enabling the interviewer to encourage further explora-
tion on items which appear to be problematic.56 58 The 
interviewer will maintain an awareness of behavioural 
cues related to specific items or questions, noting any 
signs of discomfort or distraction for example.
Interviews will be recorded and transcribed verbatim 
and thematic analysis43 will be used to analyse the tran-
scripts. The intervention tool will be adjusted, if necessary, 
following analysis of this dataset.
Phase V will finalise the format and content of the 
intervention to be subsequently tested via a multisite 
randomised controlled trial.
We anticipate the intervention to be a patient-facing 
intervention which will include information items along-
side the care pathway for patients with NSCLC and items 
related to communication around treatment decisions 
(eg, benefits/risks, side effects). We anticipate that a key 
outcome of this intervention is to enhance patient-cen-
tred communication with regard to treatment decisions.
ethIcAl consIderAtIons
The study follows the Research Governance Frameworks 
for England and Wales59 60 and guidelines from the 
National Patient Safety Agency.61 Ethical approval was 
granted in September 2015 (REC 14/WA/1103).
All participants will be able to withdraw at any point 
without impacting their medical care or relationship with 
their clinical team. Informed consent will be taken by the 
researcher collecting the data, who has undertaken Good 
Clinical Practice (research) training.
The PACT research team will preserve the confidenti-
ality and anonymity of participants and handle all research 
data according to the principles of the Data Protection 
Act.62 Transcribed recordings will be anonymised before 
analysis. Data will be stored on a password-protected 
computer located in secure university buildings and 
appropriately backed up. Data transfer across participant 
organisations will be closely monitored and contractually 
agreed. All data will be retained for up to 15 years post 
study closure. Study documents will be retained for 15 
years and then archived according to the MCPCRC policy.
PPI And steerIng grouP
PACT has established a steering group including clini-
cians and volunteer representatives, to monitor and 
guide collection and interpretation of the data.63 In line 
with guidance from Involving People64 and Involve,65 
the PACT research team has recruited two lay, actively 
involved representatives. The lay representatives will 
contribute with ideas around recruitment of participants 
and ways to describe the study. The lay representatives will 
also contribute to interpret and contextualise the study 
findings. They will review selected transcripts and their 
comments will inform the data analysis and interpreta-
tion of findings. Additionally, the lay representatives will 
guide and contribute to the dissemination of the results 
to appropriate patient groups.
dIsseMInAtIon
We hope that study findings will provide evidence for 
the development of national guidelines for care, which 
support both the regional Wales Government initiative 
of ‘achieving prudent healthcare’37 and the international 
initiative of ‘choosing wisely’, currently led by the Medical 
Royal College in the UK,66 and reduce ‘overtreatment’. 
Specific dissemination strategies of the study findings will 
include: (a) meetings with the clinicians involved into the 
study to ascertain how the study findings can enhance the 
MDT chart guidelines on best practice; (b) a lay summary 
of the study findings will be produced and disseminated 
among key patient support groups; (c) seminars will 
be given at departmental level; (d) local, national and 
international conference presentations will be made to 
disseminate both study methodology and findings; (e) 
peer-reviewed publications will include papers on the 
main study results and papers attached to specific study 
stage and methodology; (f) study newsletters will be regu-
larly produced and disseminated to key stakeholders; and 
(g) media and press releases via the Marie Curie Palli-
ative Care Research Centre and Twitter and Facebook 
accounts.
Correction notice This article has been corrected since it was published Online 
First. In the Contributor statement, the initials SC have been corrected to SS as it 
refers to name Stephanie Sivell.
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